Manuscripts

 

This section includes a list of publications related to emicizumab and specific topics of interest. The publications included aim to provide scientific, objective and balanced information about emicizumab. You can find the criteria used to collect these lists below*. They will be updated periodically by the Roche scientific team.

Due to copyrights, we can not provide access to all the publications included. If you are unable to access any of these manuscripts via your existing subscriptions, please contact your local Roche medical information department for assistance.

*The first search included all publications with the words 'emicizumab' and 'ACE910'. Due to the aim of this website, the following types of publications were not included:

  • Letter to the editor, Editorials, Commentaries and News.
  • Publications that are not specific about emicizumab.
  • Publications containing off-label information about emicizumab.
  • Publications that use emicizumab in animal models.
Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes

Camelo RM, de Medeiros TC, de Albuquerque DGB, Álvares-Teodoro J. [published online ahead of print May 7] Hematol Transfus Cell Ther. 2021 May 7:S2531-1379(21)00051-1. doi: 10.1016/j.htct.2021.02.010

Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making

Mason JA, Young G.  [published online ahead of print Jun 4] Haemophilia. 2021 Jun 4. doi: 10.1111/hae.14353

Severe bleeding after haemorrhoidal banding in a haemophilia patient treated with emicizumab

Barish J, Hajdenberg J. Haemophilia. 2021 Jul;27(4):e589-e590

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient

Harroche A, Sefiane T, Desvages M, et al. Haematologica. 2021 Aug 1;106(8):2287-2290

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor

Lefèvre CR, Jaffré A, Pontis A, et al. TH Open. 2021 May 12;5(2):e163-e165

Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy

Capdevila L, Borgel D, Lasne D, et al. Haemophilia. 2021 Jul;27(4):e581-e584

Benefits of prophylactic emicizumab in enhancing immune tolerance induction in a boy with hemophilia A and very high inhibitor titer

Sirachainan N, Chuansumrit A, Parapakpenjune S, et al. Pediatr Blood Cancer. 2021 Sep;68(9):e29111

Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit

Urbaniak-Kujda D, Biernat MM, Skalec T, et al. Haemophilia. 2021 Jul;27(4):e567-e570

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report

Warren BB, Chan A, Manco-Johnson M, Branchford BR, et al. Res Pract Thromb Haemost. 2021 Aug 3;5(5):e12571

Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile

Abarca-Villaseca V, Soto-Arellano V. Am J Case Rep. 2021 Apr 22;22:e929598

Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

Doshi BS, Witmer CM. Haemophilia. 2021 Jul;27(4):e551-e553

Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review

Villarreal-Martínez L, Sepúlveda-Orozco MDC, García-Viera DA, et al. Blood Coagul Fibrinolysis. 32(6):418-422, September 2021.

Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors

Lockhart M, Tardy-Poncet B, Montmartin A, et al. Pediatr Blood Cancer. 2021 Jul;68(7):e29041

Successful emicizumab prophylaxis during dual antiplatelet therapy for insertion of drug-eluting stents after acute coronary syndrome: A case report

Nagao A, Koganei H, Yamaguchi T, Fukutake K. Haemophilia. 2021 Jul;27(4):e549-e550

Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

Krumb E, Fijnvandraat K, Makris M, et al. [published online ahead of print Jun 30]. Haemophilia. 2021 Jun 30. doi: 10.1111/hae.14372

The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study

Schultz NH, Glosli H, Bjørnsen S, Holme PA. Res Pract Thromb Haemost. 2021 Jun 27;5(5):e12561

Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab

Teo HKW, Wong WH, Lam JCM. Haemophilia. 2021 May;27(3):e415-e418.

Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK

Hassan E, Motwani J. [published online ahead of print Jun 12]. Haemophilia. 2021 Jun 12. doi: 10.1111/hae.14358

Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays

Kizilocak H, Marquez-Casas E, Malvar J, et al. [published online ahead of print Jun 11]. Haemophilia. 2021 Jun 11. doi: 10.1111/hae.14359

The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Skinner MW, Négrier C, Paz-Priel I, et al. [published online ahead of print Jun 25]. Haemophilia. 2021 Jun 25. doi: 10.1111/hae.14363

Bispecific antibodies for the treatment of hemophilia A

Shima M. Expert Opin Biol Ther. 2021 Jun 17:1-14

Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis

Mizumachi K, Tsumura Y, Nakajima Y et al. Int J Hematol. 2021 Jun;113(6):930-935.

What proceduralists need to know about emicizumab for patients with hemophilia A

Pivalizza EG, Escobar M. Proc (Bayl Univ Med Cent). 2020 Dec 14;34(2):334-335

Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring

Barg AA, Budnik I, Avishai E, et al. Haemophilia. 2021 May;27(3):383-391

Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays

Bowyer A, Kitchen S, Maclean R. Int J Lab Hematol. 2021 Aug;43(4):O204-O206.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies

Callaghan MU, Negrier CG, Paz-Priel I. Blood. 2021 Apr 22;137(16):2231-2242.

Disruptive technology and hemophilia care: The multiple impacts of emicizumab

Hermans C, Makris M. Res Pract Thromb Haemost. 2021 May 7;5(4):e12508

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report

Ahn JH, Jung N, Shim YJ, Kim HS. Blood Res. 2021 Mar 31;56(1):44-46.

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review

Donners AAMT, Rademaker CMA, Bevers LAH, et al. [published online ahead of print, 2021 Aug 13] Clin Pharmacokinet. 2021 Aug 13. doi: 10.1007/s40262-021-01042-w

Real-world cost estimates of initiating emicizumab in US patients with haemophilia A

Samelson-Jones BJ, Guelcher C, Kuhn J, et al. Haemophilia. 2021 Jul;27(4):591-598

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A

Wang CP, Young G, Thornburg CD. Expert Opin Drug Saf. 2021 Apr;20(4):387-396.

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data

Misgav M, Brutman-Barazani T, Budnik I, et al. Haemophilia. 2021 Mar;27(2):253-260.

Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor

Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Int J Hematol. 2021 Jun;113(6):789-796

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Kempton C, Trask P, Parnes A et al. Haemophilia. 2021 Mar;27(2):221-228.

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Haemophilia. 2021 Jul;27(4):519-530

Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor

Valsecchi C, Gobbi M, Beeg M et al. J Thromb Haemost. 2021 Mar;19(3):711-718.

Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

Jonsson F, Schmitt C, Petry C. Clin Pharmacokinet. 2021 Jul;60(7):931-941

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

Agboola F, Rind DM, Walton SM, et al. J Manag Care Spec Pharm. 2021 May;27(5):667-673

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Peyvandi F, Mahlangu JN, Pipe SW et al. J Thromb Haemost. 2021;19(Suppl. 1):32-41.

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Batsuli G, Greene A, Meeks SL, Sidonio RF. Res Pract Thromb Haemost. 2021 Feb 8;5(2):342-348

Approximation of emicizumab plasma levels in emergency situations. A practical approach

Pekrul I, Pfrepper C, Calatzis G et al. Haemophilia. 2021 Mar;27(2):e214-e220.

Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway

Szanto T, Vaide I, Jouppila A, et al. Haemophilia. 2021 Jul;27(4):e571-e574

Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Shima M, Nagao A, Taki M, et al. Haemophilia. 2021 Jan;27(1):81-89.

Management of children with hemophilia A: How emicizumab has changed the landscape

Young G. J Thromb Haemost. 2021 Jul;19(7):1629-1637.

Emicizumab therapy in a haemophilia patient with previous pulmonary embolism

Holzmann J, Coulsen H, Poulsen W et al. Paediatr Child Health. 2020 Dec;56(12):2001-2002.

Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study

Yu JK, Iorio A, Chelle P, Edginton AN. Haemophilia. 2021 May;27(3):358-365

Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France

Polack B, Trossaërt M, Cousin M, et al. Haemophilia. 2021 Jan;27(1):e1-e11.

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

Pipe SW, Kruse-Jarres R, Mahlangu JN et al. J Thromb Haemost. 2021;19(Suppl. 1):21–31.

Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab

Garcia J, Zia A. Pediatr Blood Cancer. 2021 May;68(5):e28942.

Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab

Miller CH, Boylan B, Payne AB et al. Int J Lab Hematol. 2021 Apr;43(2):e84-e86.

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma

Grandoni J, Duretz V, Bonzo D et al. Haemophilia. 2021 Mar;27(2):321-328.

Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL)

von Mackensen S, Catalani O, Asikanius E, et al. Haemophilia. 2020 Nov;26(6):1019-1030.

Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors

Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. [published online ahead of print, 2021 Jan 27] Expert Rev Hematol. 2021 Jan 27:1-6. doi: 10.1080/17474086.2021.1875817.

Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child

Chehade H, Cachat F, Beck-Popovic M, et al. Pediatrics. 2020 Nov;146(5):e20200123.

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Schmitt C, Adamkewicz JI, Xu J, et al. Thromb Haemost. 2021 Mar;121(3):351-360

Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres

Stonebraker JS, Ducore JM. Haemophilia. 2021 Jan;27(1):e22-e29.

Mortality in congenital hemophilia A – A systematic literature review

Hay CRM, Nissen F, Pipe SW. J Thromb Haemost. 2021;19(Suppl. 1):6-20.

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US

Lewandowska M, Randall N, Bakeer N, et al. Haemophilia. 2021 Jan;27(1):90-99.

Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise

Lowe A, Kitchen S, Jennings I, et al. Haemophilia. 2020 Nov;26(6):1087-1091.

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

Kizilocak H, Marquez-Casas E, Phei Wee C, et al. Haemophilia. 2021 Jan;27(1):164-172.

Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study

Mancuso ME, Mahlangu J, Sidonio R Jr, et al.  Haemophilia. 2020 Nov;26(6):1009-1018.

Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

Escuriola-Ettingshausen C, Auerswald G, Königs C, et al.  Haemophilia. 2021 May;27(3):e305-e313

Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor

Chen YW, Chen WJ, Tseng MS, et al. Haemophilia. 2021 May;27(3):e385-e388

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Yoneyama K, Schmitt C, Kotani N, et al. Clin Pharmacokinet 2018;57:1123–1134.

Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis

Batsuli G, Zimowski KL, Tickle K, et al. Haemophilia 2019;25:789–796.    

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

Retout S, Schmitt C, Petry C, Mercier F, Frey N. [published online ahead of print, 2020 Jun 5]. Clin Pharmacokinet. 2020;10.1007/s40262-020-00904-z.

Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors

Cortesi PA, Castaman G, Trifirò G, et al. Thromb Haemost. 2020;120(2):216-228.

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A

Zhou ZY, Raimundo K, Patel AM, et al. J Manag Care Spec Pharm 2020:1–12.

Concomitant Use of rFVIIa and Emicizumab in People With Hemophilia A With Inhibitors: Current Perspectives and Emerging Clinical Evidence

Linari S and Castaman G. Ther Clin Risk Manag 2020;16:461–469.

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro.

Noguchi-Sasaki M, Soeda T, Ueyama A, et al. TH Open 2018;2:e96–e103.    

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Sampei Z, Igawa T, Soeda T, et al. PLoS One 2013;8:e57479.

Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

Barg AA, Livnat T, Budnik I, et al. [published online ahead of print, 2020 Jul 12]. Br J Haematol. 2020;10.1111/bjh.16964.

A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X

Ogiwara K, Nogami K, Matsumoto N, et al. [published online ahead of print, 2020 Aug 3]. Int J Hematol. 2020;10.1007/s12185-020-02959-x.

Emicizumab treatment: Impact on coagulation tests

Nougier C, Jeanpierre E, Ternisien C, et al. [published online ahead of print, 2020 Jul 15]. Eur J Haematol. 2020;10.1111/ejh.13490.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

Oldenburg J, Shima M, Kruse-Jarres R, et al. [published online ahead of print, 2020 Aug 9]. Pediatr Blood Cancer. 2020;e28474.

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. [published online ahead of print, 2020 Jul 27]. Thromb Haemost. 2020;10.1055/s-0040-1714279.

Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study

Khoo L, Matthews S, Kershaw G, et al. Haemophilia. 2020 Nov;26(6):e340-e342

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

Shima M, Hanabusa H, Taki M, et al. N Engl J Med 2016;374:2044–53.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. Haemophilia. 2019;25(4):676-684.

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects

Li H, Zhang W, Petry C, et al. Clin Pharmacol Drug Dev. 2021 Jan;10(1):30-38

Spotlight on Emicizumab in the Management of Hemophilia A: Patient Selection and Special Considerations

Yada K and Nogami K. J Blood Med 2019;10:171–181.

Anti-factor IXa/X Bispecific Antibody (ACE910): Hemostatic Potency Against Ongoing Bleeds in a Hemophilia A Model and the Possibility of Routine Supplementation.

Muto A, Yoshihashi K, Takeda M, et al. J Thromb Haemost 2014;12:206–213.

Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

McCary I, Guelcher C, Kuhn J, et al. Haemophilia. 2020;26(4):631-636.

Non‐additive effect on thrombin generation when a plasma‐derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro

Bravo MI, Raventós A, Pérez A, Costa M, Willis T. J Thromb Haemost. 2020;18(8):1934-1939.

Laboratory issues in gene therapy and emicizumab

Bowyer AE, Lowe AE, Tiefenbacher S. Haemophilia. 2021 Feb;27 Suppl 3:142-147

A Multicenter, Open-Label Phase 3 Study of Emicizumab Prophylaxis in Children With Hemophilia A With Inhibitors

Young G, Liesner R, Chang T, et al. Blood 2019;134:2127–2138.

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia

Shima M. Res Pract Thromb Haemost. 2020;4(4):446-454.

Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation

Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. J Thromb Haemost. 2020 Sep;18(9):2205-2208

Emicizumab should be prescribed independent of immune tolerance induction

Le Quellec S, Negrier C. Blood Adv. 2018;2(20):2783-2786.

Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events

Patel AM, Corman SL, Chaplin S, et al. J Med Econ 2019;22:1328–1337.

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program

Levy GG, Asikanius E, Kuebler P, et al. J Thromb Haemost 2019;17:1470–1477.

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Ebbert PT, Xavier F, Seaman CD, et al. Haemophilia 2020;26:41-46. DOI: 10.1111/hae.13877.

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors

Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Br J Haematol. 2020 Sep;190(5):727-735

Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A

Lippi G, Favaloro EJ. Adv Clin Chem. 2019;88:151-167.

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

Shima M, Nogami K, Nagami S, et al. Haemophilia. 2019;25(6):979-987.

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Le Quellec S. Drug Des Devel Ther. 2020;14:469-481

Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment

Valke LLFG, Beckers EAM, Blijlevens NMA, van Heerde WL, Schols SEM. Haemophilia. 2020 Nov;26(6):e327-e330

Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons With Hemophilia A.

Retout S, Schmitt C, Petry C, et al. Clin Pharmacokinet 2020;doi: 10.1007/s40262-020-00904-z (epub ahead of print).

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Young G. Blood Adv. 2018;2(20):2780-2782.

Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

Reyes A, Révil C, Niggli M, et al. Curr Med Res Opin. 2019;35(12):2079-2087.

Evaluating the safety of emicizumab in patients with hemophilia A

Langer AL, Etra A, Aledort L. Expert Opin Drug Saf. 2018;17(12):1233-1237.

Factor VIIIa-mimetic Cofactor Activity of a Bispecific Antibody to Factors IX/IXa and X/Xa, Emicizumab, Depends on Its Ability to Bridge the Antigens.

Kitazawa T, Esaki K, Tachibana T, et al. Thromb Haemost 2017;117:1348–1357.

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort

Barg AA, Avishai E, Budnik I, et al. Pediatr Blood Cancer 2019;66(11):e27886. DOI: 10.1002/pbc.27886.

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII‐deficient plasma, similar to the addition of factor VIII

Shimonishi N, Nogami K, Ogiwara K, et al. Haemophilia. 2020;26(3):e97-e105.

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

Yada K, Nogami K, Ogiwara K, et al. Int J Hematol 2019;110:419–430.    

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Pipe SW, Shima M, Lehle M, et al. Lancet Haematol 2019;6:e295–e305.

Emicizumab: A Review in Haemophilia A

Blair, H.A. Drugs 79, 1697–1707 (2019).

First report of emicizumab use in a female patient with severe hemophilia A

Verstraete G, Lambert C, Hermans C. Blood Adv. 2020;4(13):2950-2952.

Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban

Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F. J Thromb Thrombolysis. 2020;49(3):413-419.

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Adamkewicz JI, Chen DC, Paz-Priel I. Thromb Haemost. 2019;119(7):1084-1093.

The Effect of Emicizumab Prophylaxis on Health-Related Outcomes in Persons With Haemophilia A With Inhibitors: HAVEN 1 Study

Oldenburg J, Mahlangu J, Bujan W, et al. Haemophilia 2019;25:33–44.

Emicizumab for the prevention of bleeds in hemophilia A

Mahlangu J. Expert Opin Biol Ther. 2019;19(8):753-761.

Thromboprophylaxis in a patient with COVID‐19 and severe hemophilia A on emicizumab prophylaxis

Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, Martín Salces M, García-Barcenilla S, Jiménez-Yuste V. J Thromb Haemost. 2020 Sep;18(9):2202-2204

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol 2018;183:257–266.

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol 2018;183:257–266.

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro

Minami H, Nogami K, Yada K, et al. J Thromb Haemost. 2019;17(1):126-137.

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A

Müller J, Pekrul I, Pötzsch B, et al. Thromb Haemost 2019;119:1384–1393.

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Kotani N, Yoneyama K, Kawakami N, et al. Clin Pharmacol Drug Dev 2019;8:702–712.

Emicizumab for the treatment of haemophilia A: a narrative review

Franchini M, Marano G, Pati I, et al. Blood Transfus. 2019;17(3):223-228.

A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement

Hooimeijer HL, Lukens MV, Verhagen MV, Meijer K, Stein-Wit MA, Tamminga RYJ. Haemophilia. 2020;26(3):e138-e140.

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.

Minami H, Nogami K, Yada K, et al. J Thromb Haemost 2019;17:126–137.

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies

Nogami K, Soeda T, Matsumoto T, et al. J Thromb Haemost 2018;16:1383–1390.    

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol. 2018;183(2):257-266.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A Without Inhibitors

Mahlangu J, Oldenburg J, Paz-Priel I, et al. N Engl J Med 2018;379:811–822.

Emicizumab for hemophilia A without inhibitors

Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Expert Rev Hematol. 2019;12(7):515-524.

Total knee replacement with and without emicizumab: a unique comparison of perioperative management

Evans MS, Davis C, Eyster ME. Blood Adv. 2020;4(5):855-857.

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Shima M, Nogami K, Nagami S, et al. Haemophilia 2019;25:979–987.

Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

Nakajima Y, Nogami K, Yada K, et al. Thromb Haemost 2020;120:968–976.

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

Noguchi-Sasaki M, Soeda T, Ueyama A, et al. TH Open. 2018;2(1):e96-e103.

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab

Nogami K, Matsumoto T, Tabuchi Y, et al. J Thromb Haemost 2018;16:1078–1088.

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Shima M, Hanabusa H, Taki M, et al. Blood Adv 2017;1:1891–1899.

Emicizumab: Review of the literature and critical appraisal

Rodriguez-Merchan EC, Valentino LA. Haemophilia. 2019;25(1):11-20.

Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring

Biron-Andreani C, Diaz-Cau I, Ranc A, et al. Br J Haematol. 2020;189(3):e100-e103.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Kitazawa T and Shima M. Int J Hematol 2020;111:20–30.

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A

Yoneyama K, Schmitt C, Kotani N, et al. Clin Pharmacokinet. 2018;57(9):1123-1134.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Oldenburg J, Mahlangu JN, Kim B, et al. N Engl J Med 2017;377:809–818.

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

Mahlangu JN. BioDrugs. 2018;32(6):561-570.

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors

Okamoto S, Suzuki N, Suzuki A, et al. TH Open. 2019;3(4):e364-e366.

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.

Shimonishi N, Nogami K, Ogiwara K, et al. Haemophilia 2020;26:e97–e105.

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Kitazawa T, Esaki K, Tachibana T, et al. Thromb Haemost. 2017;117(7):1348-1357.

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Shima M, Hanabusa H, Taki M, et al. N Engl J Med. 2016;374(21):2044-2053.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

Kitazawa T, Shima M. Int J Hematol. 2020;111:20–30.

ST‐Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

Gundabolu K, Goldsweig A, Bhatt VR, Koepsell SA, Harper JL. Haemophilia. 2020;26(1):e5-e8.

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

Sampei Z, Igawa T, Soeda T, et al. MAbs. 2015;7(1):120-128.

A First-In-Human Phase 1 Study of ACE910, a Novel Factor VIII-mimetic Bispecific Antibody, in Healthy Subjects

Uchida N, Sambe T, Yoneyama K, et al. Blood 2016;127:1633–41.

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A

Knight T, Callaghan MU. Therap Adv Hem. 2018;(Oct), 319–34.

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Haematologica. 2019;104(8):e380-e382.

Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays.

Peyvandi F, Kenet G, Pekrul I, et al. J Thromb Haemost 2020;18:1242–1255.

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

Sampei Z, Igawa T, Soeda T, et al. PLoS One. 2013;8(2):e57479.

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A

Díaz-Ricart M, Isola IM, Escolar G. Drugs Today (Barc). 2018;54(10):591-600.

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays

Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. Ther Adv Hematol. 2019;10:2040620719860025.

Emicizumab for hemophilia A with factor VIII inhibitors

Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Expert Rev Hematol. 2018;11(11):835-846.

Emicizumab use in major orthopedic surgery

Seaman CD, Ragni MV. Blood Adv. 2019;3(11):1722-1724.

Emicizumab-kxwh: First Global Approval

Scott LJ, Kim ES. Drugs. 2018;78(2):269-274.

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra‐atrial thrombosis in severe haemophilia with an inhibitor

Weyand AC, Dorfman AL, Shavit JA, Pipe SW. Haemophilia. 2019;25(3):e203-e205.

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Lenting PJ, Denis CV, Christophe OD. Blood. 2017;130(23): 2463–2468.

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Haematologica. 2018;103(4):e181-e183.

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.

Furukawa S, Nogami K, Shimonishi N, et al. Br J Haematol 2020; DOI: 10.1111/bjh.16574 (ePub ahead of print).

A new era of treatment for patients with haemophilia A?

Klamroth R. Hamostaseologie. 2017;37(3):216-218.

Bispecific antibody mimicking factor VIII

Nogami K. Thromb Research. 2016; 141:supp 2, S34-35.

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.

Adamkewicz JI, Chen DC and Paz-Priel I. Thromb Haemost 2019;119:1084–1093.

Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.

Sampei Z, Igawa T, Soeda T, et al. MAbs 2015;7:120–8.